Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2018

View Archived Issues

Next-generation polymyxins could bring immunotherapy to antibiotics

New hSTING agonists presented as cancer immunotherapy agents

pAAV.CMV.miR204 shows protective effect on photoreceptors in models of inherited retinal disease

Researchers unveil NAXD gene as causative of a neurodegenerative disorder

Compound CAR T cells targeting CLL1 and CD33 in refractory acute myeloid leukemia: phase I results

First human data presented for prostate cancer imaging agent [68Ga]PSMA-093

Embryonic stem cells make helpful heart muscles

New mutations in SLC25A24 gene found to cause Fontaine syndrome

Pivotal phase III trial of Pixuvri in B-cell NHL does not meet primary endpoint

Promising interim data presented from phase I study of oral carbapenem SPR-994

Assembly Biosciences initiates phase IIa studies of ABI-H0731 for HBV

Codexis begins dosing in first-in-human study of CDX-6114 for PKU

Phase III trial of luspatercept in transfusion-dependent beta-thalassemia meets primary endpoint

Intrapulmonary penetration of ETX-2514SUL supports development for respiratory infections

MediciNova announces subgroup analyses from trial of MN-166 in ALS

Catabasis announces plans for phase III trial of edasalonexent in DMD

Bellus Health initiates phase I study of BLU-5937 for the treatment of chronic cough

Matinas collaborates with NINDS to develop HIV therapy based on LNC platform

CPL-207-280CA demonstrates improved glycemic control and safety in vivo

Amgen discovers new beta-secretase inhibitors

KCNC1/KCNC2 channel modulators presented by Autifony Therapeutics

Pfizer divulges glucagon-like peptide 1 receptor agonists

Cassiopea reports phase III topline results for topical antiandrogen Winlevi for acne

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...